Anti-proliferative agent Sildenafil showed statistically greater effects on vessel structure than that seen in both RP5063 groups and improved oxygen saturation. Additionally, Sildenafil did not demonstrate any significant effect on arterial obliteration, plexiform lesion development, or pulmonary arterial or right ventricular pressure. As PAH gains in severity, the impact of RP5063 inhibition of 5HT 2B increases, preventing arterial constriction and improving pulmonary hemodynamics. Due to its functional, structural, and chemokine effects, RP5063 represents a promising candidate for investigation in late-phase PAH.
RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats Pulmonary arterial hypertension (PAH) is a progressive condition defined by increased pulmonary artery pressure due to pulmonary arterial constriction/remodeling (Bogaard et al., 2009; Frumkin, 2012) . These changes cause right ventricle (RV) pressure overload, hypertrophy, and failure, leading to death (Kamar et al., 2016; Voelkel et al., 2006) . PAH affects 15-50 cases per 1,000,000 (Peacock et al., 2007) . Survival rates at 5 and 7 years following diagnosis are 57% and 49%, respectively (Benza et al., 2012) .
Treatment involves use of the following strategies: 1-decreasing phosphodiesterase 5 (PDE-5) expression; 2-blocking endothelin; and 3-supplementing prostacyclins (Christman et al., 1992; Corbin et al., 2005; Galie et al., 2009; Humbert et al., 2004a Humbert et al., , 2004b McLaughlin et al., 2009 ). However, these approaches fail to ameliorate the underlying cytoproliferation that influences the pulmonary vascular structure (Zopf et al., 2011) . Thus, new therapies are needed to stem these cytoproliferative processes that influence PAH development and progression.
Modulation of serotonin (5-HT) is of great interest. This mediator exerts its effects through the 5-HT 1B/2A/2B receptors and the 5-HT transporter (SERT); all are enhanced in pulmonary artery smooth muscle and endothelial cells in the setting of PAH (Baliga et al., 2011; Dumitrascu et al., 2011; Esteve et al., 2007; Farber and Loscalzo, 2004; Humbert et al., 2004a Humbert et al., , 2004b MacLean and Dempsie, 2010) . These 5-HT-receptor and SERT interactions stimulate pulmonary artery smooth muscle cell and fibroblast proliferation, leading to medial layer thickening and pulmonary artery narrowing and remodeling (Welsh et al., 2004) .
Evidence suggests that 5-HT receptor targeting can influence the pathogenesis of PAH (Dumitrascu et al., 2011; Liu et al., 2012; Porvasnik et al., 2010; Welsh et al., 2004) . SB204741, a 5-HT 2B antagonist, was found to reduce inflammatory cell recruitment to the lungs, pulmonary artery smooth muscle muscularization, and vascular stiffness by limiting 5-HT effects on Src tyrosine kinase and downstream activity (West et al., 2016) . Terguride, a potent 5-HT 2A/2B antagonist, was reported to suppress pulmonary vessel smooth muscle inflammatory histopathologic changes and proliferation, reduce inflammatory cytokines, and inhibit pulmonary vasoconstriction (Dumitrascu et al., 2011) . PRX08066, a 5-HT 2B antagonist, was shown to reduce vascular remodeling, pulmonary arterial pressure (PAP), and RV hypertrophy (Porvasnik et al., 2010; Shacham et al., 2006) . Rosiglitazone, a peroxisome proliferator-activated receptor γ agonist, was demonstrated to reverse pulmonary artery vasoconstriction and thickening due to 5-HT 2B induction (Liu et al., 2012) .
RP5063, a novel, multimodal dopamine (DA) and 5-HT modulator, shows high affinity for DA 2/3/4 and 5-HTR 2A/2B//7 receptors and moderate affinity for SERT (Cantillon et al., 2017) . Targeting multiple 5-HT receptors may provide an attractive option for PAH, while potentially reducing comorbid mental disorders that can exist in up to 35% of PAH patients (Verma et al., 2016) . RP5063 brings an established efficacy, safety, and pharmacokinetic profile based on data from a phase 1 evaluation and phase 2 studies of acute schizophrenia and schizoaffective disorders (Cantillon et al., 2017) .
This study was undertaken to evaluate RP5063 efficacy in the mitigation of the symptoms of PAH induced by Sugen 5416 and hypoxia (SuHx) in rats.
Materials and methods

Experimental design
In this parallel-design study, 38 male Wistar-Kyoto rats (weights: 200-250 g; ages: 10-12 weeks; Charles River Laboratories, St Constant, Quebec, Canada) were randomized according to their body weight into five experimental groups. The study schedule was such that an equal number of animals per treatment group were monitored and processed on each terminal surgery day (when possible).
The institutional animal ethics committee of IPS Therapeutique (IPST) approved the study in accordance with the principles of the Canadian Council on Animal Care (CCAC). IPST identified, housed, and cared for the animals per the CCAC guidelines.
On Day 0, dimethyl sulfoxide (DMSO; Sigma-Aldrich Canada Ltd.) solution (0.5 ml) was injected subcutaneously into five healthy animals (Group 1), and Sugen solution (SU5416, 10 mg/ml diluted in DMSO, Sigma-Aldrich Canada Ltd.) dosed at 20 mg/kg was administered subcutaneously to 33 animals (Groups 2-5). Animals in Groups 2-5 were kept under hypoxic conditions (FiO 2 of 10%) for 3 weeks (Days 0-21), then in ambient oxygen levels (FiO 2 of 21%) for 2 weeks . From Day 14-35, these animals were gavaged b.i.d. as follows: 1-Group 2 (vehicle, SuHx+veh; n=8); 2-Group 3 (RP5063 10 mg/kg (RP-10); n=10); 3-Group 4 (RP5063 20 mg/kg (RP-20); n=10); and 4-Group 5 (sildenafil 50 mg/kg (Sil-50); n=5).
The 10 and 20 mg/kg b.i.d. doses of RP5063 were prepared by dissolving 300 or 600 mg of active drug into 400 ml of sterile 5% glucose solution, resulting in solutions of 0.75 mg/ml or 1.5 mg/ml, respectively. For sildenafil, 1895 mg of active drug was dissolved in 500 ml of sterile 5% glucose solution to obtain a solution of 3.79 mg/ ml. To deliver the vehicle or treatment, the investigators administered 13.33 ml/kg of the resultant solutions b.i.d.
During the treatment period, the rats were given food and water ad libitum. They were observed daily for behavior and general health status, and had blood samples, body weights, and body temperature taken weekly.
On Day 35, anesthetized animals were instrumented. Hemodynamic parameters were recorded continuously for at least 5 min or until loss of quality in the PAP signal. These recordings involved moving a flexible fluid filed catheter attached to a pressure transducer from the right ventricular (RV) cavity, through the pulmonary valve, into the pulmonary artery and observing the clear transitions in diastolic pressures and general pressure waveforms, as the catheter transitioned from the ventricle into the artery. At the end of the recording, a blood sample was collected. After the animal was exsanguinated, the pulmonary circulation was flushed with 0.9% NaCl, and tissues were harvested for further analysis.
Parameters measured on surgery day
On Day 35, a variety of parameters were obtained. Cardiac activity was monitored using three electrocardiographic (ECG) contact electrodes (Harvard BioSciences Inc., Holliston, MA) placed in a lead-I/II configuration and connected to an IsoDam8 differential amplifier (World Precision Instruments, LLC, Sarasota, FL). Heart rate (HR) was recorded using duplicate systems: from the ECG records (RRintervals) and using an N-595 pulse oximeter (Nellcor, Plymouth, MN) attached to the left front paw of the animal. Blood oxygen saturation (SO 2 ) was measured using a pulse oximeter signal attached to the left front paw of the animal. Saturation values were measured in percentages using cursor readings in Clampfit 10.2.014.
Systemic arterial blood pressure (SAP) was monitored using an intra-arterial fluid-filled catheter connected to a pressure transducer (AD Instruments, Colorado Springs, CO), with diastolic and systolic pressures values measured in mm Hg using Clampfit 10.2.0.14. Calculation of mean SAP (mSAP) and pulse pressure (PP) used the following formulas: 1-mSAP = diastolic systemic pressure + ([systolic systemic pressure -diastolic systemic pressure] / 3); and 2-PP = systolic systemic pressure -diastolic systemic pressure.
RV systemic pressure (RVSP) and PAP were measured using an intraventricular fluid-filled catheter connected to a pressure transducer (AD Instruments). Diastolic and systolic pressures were measured in mm Hg using Clampfit 10.2.0.14 readings. Calculation of mean RVSP (mRVSP) and mean PAP (mPAP) values was performed as described for the mSAP. All hemodynamic parameters were digitized using a Digidata 1440A interface (Axon Instrument Inc., Foster City, CA), and acquired/displayed using Axoscope 10.2.0.14 (Axon Instrument Inc).
Organ weights were expressed as relative percentages and were calculated as follows: Relative organ weight = (organ weight × 100) / body weight. For the heart, Fulton's index (RV vs. left ventricle ratio) was calculated as such: Fulton's index = RV weight / (left ventricular + septum (LV+S) weight).
Histological preparation and categorization
Trachea, lungs, and heart were removed together; the liver was extracted separately. All tissues were weighed, including the right and left lobes of the lung, as well as the wet weights of the RV and LV+S. All tissues were fixed by perfusion in 10% neutral buffered formalin (NBF).
A transversal section of the middle left lobe was cut and forwarded in 10% NBF to the Institute for Research in Immunology and Cancer (Montreal, Quebec, Canada). Tissues were embedded, sliced (5-µm thickness), mounted, and conventionally stained with hematoxylin and eosin (H & E). Glass slides containing fixed and stained tissues were then visualized at 200 × magnification (Eclipse T100 microscope, Nikon, Melville, NY). At least 15 non-overlapping view fields/lung were selected for microphotographs (Nikon DS-Fi1 digital camera with Nikon NIS Elements 4.30, Nikon, and Melville, NY).
All vessels in a tissue section were analyzed, from largest to smallest, with no threshold or limit set in vessel size. Intra-acinar vessels were included. Vessels associated with terminal bronchioles and all larger airways were excluded. Vessels were divided based on lumen diameter: 1-small (10-50 µm); 2-medium (50-100 µm); and 3-large ( > 100 µm). Diameters were measure using Infinity Analyze software v5.03 (Lumenera Corp., Ottawa, Ontario, Canada) at the widest point of the lumen, measured perpendicular to the long axis of the vessel. Vessels were categorized based on muscularity: 1-complete, defined as coverage greater than 90% circumference surrounded by a smooth muscle layer; 2-partial, defined as coverage between 10% and 90% circumference surrounded by a smooth muscle layer, along with a crescent of smooth muscle and two elastic laminae for part of the circumference; and 3-non-muscular, defined by a single elastic lamina for the entire circumference ( < 10%) of the vessel with no apparent smooth muscle layer.
Microphotographs were examined for plexiform-like lesion, a hallmark characteristic of severe PAH, and luminal obliterations. For this analysis, "obliterated vessels" were those in which more than 50% of the luminal space was taken up by lesions made of endothelial cells. Projecting lesions which were aneurysm-like were not calculated: they represented endothelial cell proliferations, but did not limit luminal space, and therefore were not expected to impede blood flow and contribute to the increased pulmonary arterial pressure, in this group presenting with 50%+ obliteration of the luminal space.
Chemokine quantification
Blood samples were obtained on Days 0 (pre-induction), 21 (end of hypoxia), 28, and 35 (terminal surgery). On Day 35, blood samples were collected immediately following completion of the hemodynamic measurements. One-half of each sample was saved for analysis of leukotriene (LT)-B4. This inflammatory mediator was quantified for the no-SuHx, SuHx+veh, and RP-10 and −20 groups at all time points. For Sil-50, only LT-B4 was quantified for samples obtained on Days 21 and 28. The blood was centrifuged (1000×g for 10 min) to obtain plasma, which was stored frozen until all the samples had been collected. LT-B4 levels were detected by quantitative enzyme-linked immunosorbent assay (Abcam, Cambridge, UK). All circulating levels were extrapolated from their respective standard curves. All tests were either colorimetric or fluorescence-based.
Statistics
Values were presented as means ± standard error of means (S.E.M.). Repeated unpaired Student t tests using Excel 2007 (Microsoft, Redmond, WA) and/or GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA) were performed on all experimental conditions. Comparisons included: 1-SuHx+ vehicle (SuHx+veh; Group 2) versus non-induced healthy animals (No-SuHx; Group 1) to confirm the successful induction of the disease; and 2-treatment (Groups 3-5) versus SuHx+Veh (Group 2). Statistical comparisons using a two-tailed t test (GraphPad Software Inc.) were made between the RP5063 and Sil-50 groups based on relevant findings in which the magnitude of difference between these treatment groups would indicate the need for statistical evaluation. For the chemokine analysis, a one-way analysis of variance with Dunn's post-hoc statistical tests were used to identify statistically significant changes in circulating levels for each of the cytokines or mediators analyzed. Statistical significance was declared if P < 0.05.
Results
Animal Disposition
Of the 38 animals, 8 animals died in their cages during the course of the study: 1-one from Group 1 (20%); 2-three from Group 2 (37.5%); 3-one from Group 3 (10%); 4-two from Group 4 (20%); and 5-one from Group 5 (20%). Mortality rates for this study were in the upper range of what is considered expected mortality in this model (Akagi et al., 2016; Abe et al., 2004) ; Sugen 5416 is known to be a variable potency. It is likely that the reagent induced a more rapid onset of the endothelial dysfunction, contributing to higher death rates. Five animals treated with RP5063 (three: RP-10; two: RP-20) were excluded as "non-responders" on the basis of the Grubbs statistical outlier test, with the number of outliers estimated based on diastolic PAP (PAP Diast ) values, as well as examination of the hemodynamic and ECG records, looking specifically for ventricular dysfunction, defined as low pulse pressure amplitude, ST segment deviation and T wave inversions. Those animals which exhibited changes in ECG records indicative of the most severe cardiac dysfunction (Bonderman et al., 2011) exhibited the expected extent of PAH, but were non-responsive to either treatment. This observation was in complete agreement with clinical reports stating that up to 84% of PAH patients with cardiovascular dysfunction are less likely to respond to current PAH therapies, such as Riociguat (Bonderman et al., 2013) and Sildenafil (Redfield et al., 2013) , as quantified by symptom severity and exercise capacity (Charalampopoulos et al., 2014) . In total, 24 animals were left for analysis.
Systemic Hemodynamic and Cardiac Parameters (Day 35, Surgery)
Table 1 summarizes the systemic hemodynamic and cardiac parameters at the time of surgery. PP, mSAP, diastolic SAP (SAP Diast ) systolic SAP (SAP Syst ) and heart rate (HR) did not differ among all groups.
Pulmonary hemodynamic and respiratory parameters (Day 35, Surgery)
Fig. 1A-D illustrates pulmonary hemodynamic parameters at surgery: (PAP Diast ), systolic pulmonary pressure (PAP Syst ), mean PAP (mPAP), RV systolic pressure (RVSP), and oxygen saturation (SO 2 ). As compared with the healthy animals in the no-SuHx group, those in the SuHx+veh group had higher PAP Diast (17 versus. 12.3 mm Hg; Δ Animals treated with RP5063 showed improvement in PAP Syst and RVSP over the SuHx+veh group even if the mPAP did not reach significance (RP-10: P=0.06 and RP-20: P=0.08). Both, the RP-10 and RP-20 groups had significantly lower PAP Syst at 32.2 mm Hg (Δ -25.1%) and 32 mm Hg (Δ -25.5%), respectively (P < 0.05). In addition, the RP-10 group reflected a significant reduction in RVSP as compared with the SuHx+veh group (32.8 versus 42.8 mm Hg; Δ -23.3%; P=0.011).
Relative to SO 2 , animals in the RP-20 and the Sil-50 groups showed improvements over the SuHx+veh group (Fig. 2) . SO 2 in RP-20 animals was 3% higher at 96.9% and the Sil-50 group was 3.1% higher at 97% (P < 0.05). Table 2 reflects body temperature, weight gain, and relative lung, liver, and trachea weight comparisons. Animals in the SuHx+veh group exhibited lower weight gain (49.8 g vs. 84.5 g; p˂0.05) and a higher relative lung weight (0.71% vs. 0.49%; p˂0.05) as compared with those animals in the No-SuHx group. No statistical differences were seen with the RP5063 and sildenafil groups, as compared with the SuHx +veh group, with respect to temperature, weight gain, and relative lung weight. All treatment groups showed higher weight gain, when compared with SuHx+veh. The RP-10 and RP-20 and Sil-50 showed 66.7 g, 50.8 g, and 64.0 g increases, respectively. Interestingly, the relative lung weight for Sil-50 group was 0.71%, whereas the relative lung weight for the RP-10 and RP-20 groups were 0.65% and 0.62%, respectively. The only significant organ weight observation was a lower relative liver weight observed in the RP-20 group (3.07% vs. 3.43%; P < 0.01). Table 3 and Fig. 4A highlight the effect of treatment on the percentage of muscular, semi-muscular, and non-muscular vessels. Differences were noted between the SuHx+veh and No-SuHx groups with respect to percentages of smooth muscle tissue (78.8%; P < 0.001) and non-muscular tissue (-73.2%; P < 0.001). With respect to muscular tissue, RP5063-treated animals had a lower percentage than SuHx+veh by 25.8%, and 48.4% in the 10 and 20 mg/kg BID groups, respectively (P < 0.001). The Sil-50 group exhibited a lower percentage of muscular tissue by 60.3% (P < 0.001) compared with the SuHx+veh group. (34.5%), as compared with the RP-10 group (P < 0.001), and by 11.9% as compared with the RP-20 group (P < 0.05). With regard to non-muscular tissue, the RP5063 groups displayed a higher percentage than the SuHx+veh group by 20.14% and 43.17% in the 10 and 20 mg/ kg b.i.d. groups, respectively (P < 0.001). The Sil-50 group reflected a higher percentage of non-muscular tissue by 54.54% compared with the SuHx+veh group (P < 0.001), by 34.4% as compared with the RP-10 group (P < 0.05), and by 11.37% as compared with the RP-20 group (P < 0.05). Fig. 4B illustrates the effect of treatment on vessel wall thickness. Small wall thicknesses increased by 26.49% (P < 0.001) in the SuHx +veh group versus the No-SuHx-induced group. With respect to treatment, RP-20 decreased wall thickness by 18.96% (p˂0.01) while Sil-50 did the same by 25.48% (P < 0.01) versus the SuHx+veh group. The wall thickness for small vessels was less for RP5063 in the RP-20 group by 18.96% (p˂0.01) and for sildenafil Sil-50 by 25.48% (P < 0.01).
Systemic parameters
Histological Findings
SU 5416 induction ( Fig. 5A-E ) resulted in combinations of small pulmonary medial and adventitial thickening and some arteriopathy, including concentric neointimal and complex plexiform-like lesions, a hallmark of clinical PAH, which is only reproduced in Sugen-Hx animal models. The lungs of SU 5416-treated rats showed a range of luminal obliterations, from light to severe, in medium-sized and small pulmonary arteries, all caused by endothelial cell proliferation. There were two patterns of complex lesion formation observed: one with the lesion forming within the vessel lumen and essentially obliterating the luminal space, and another that projected outside the vessel (aneurysm-like).
Compared with the No-SuHx animals, which exhibited normal vascular and alveolar structures (Fig. 5A) , those in the SuHx+veh ; difference between the negative control (SuHx+veh). c P < 0.001; difference between sildenafil and RP5063 10 mg/kg group (% muscular). d P < 0.05; difference between sildenafil and RP5063 20 mg/kg group (% muscular). e P < 0.001; difference between sildenafil and RP5063 10 mg/kg and 20 mg/kg groups (% non-muscular).
L. Bhat et al. European Journal of Pharmacology 810 (2017) 83-91 suffering from PAH presented with significantly figure vascular walls, characterized by vascular smooth muscle (VSM) cell hypertrophy and hyperplasia (Fig. 5B) . Furthermore, a number of plexiform lesions characteristic of clinical PAH were also observed in induced, but nontreated animals. The remodeling of the pulmonary vasculature in RP5063-or sildenafil-treated animals was less severe; VSM cell hyperplasia was essentially nonexistent, with cell hypertrophy accounting for most of the intimal thickening in treated animals. Finally, no plexiform lesion could be observed in any of the treated animals. As a result of the diminished endothelial hyperplasia, and VSM cell hypertrophy and hyperplasia, vascular luminal diameters remained greater, limiting the obliteration of the blood vessels by plexiform lesions and vascular remodeling. Endothelial cell obliteration of small and medium pulmonary vessels occurred after the animals were returned to normoxic conditions. The animals in the SuHx+veh group exhibited between 10% and 15% arterial obliteration due to endothelial cell proliferation. With both doses of RP5063, arterial obliteration was observed in 8% of the vessels. Sildenafil did not impact endothelial obliteration, as seen in 13% of the vessels. Fig. 6 highlights the effects of RP5063 on LT-B4. Changes in the levels of this chemokine were pronounced in the SuHx+veh group on Day 21 and remained high on Days 28 and 35. Levels of this inflammatory mediator were much lower in the RP5063 than those seen in both the SuHx+veh and Sil-50 groups on Days 21 and 28. This difference in LT-B4 levels in the RP5063 and SuHx+veh groups was much less on Day 35. None of the differences seen between these groups were statistically significant.
Chemokine findings
Discussion
SuHx-induced PAH model
In this widely-used model, SU5416, a vascular endothelial growth factor (VEGF)-receptor antagonist known to cause pulmonary endothelial lesions in the pulmonary vasculature, facilitating pulmonary artery vasoconstriction resulting from both the hypoxic conditions and the endothelial damage that decreases nitric oxide and endotheliumderived relaxing factor levels (Gomez-Arroyo et al., 2016; Stenmark et al., 2009) . By obstructing the pulmonary arterioles and limit pulmonary blood flow, these changes increase PAP, RV afterload, and hypertrophy.
In this study, animals in the SuHx+veh group developed severe PAH. The significant increase in the PAPs increased the RV afterload and RV hypertrophy, as reflected by the 43% increase in Fulton's index. The fall in SO 2 reflected the effect on systemic oxygenation.
Another characteristic included the increase in lung weight, despite a lower body weight gain, as compared that in the No-SuHx group. This finding suggested lung edema, fibrosis, and remodeling. The lung edema contributed to higher respiratory resistance, 1.7-fold higher than that in the No-SuHx group.
Morphologic changes patterned the functional changes seen in the SuHx+veh group. Induction affected vessel wall composition and thickness, particularly in the smaller vessels, as compared with the No-SuHx group. Muscular arterioles dominated the composition of the lung tissue in the SuHx+veh group, in contrast to the predominance of non-muscular arterioles in the No-SuHx group. The SuHx+veh group also displayed a significantly thicker muscular layer in the small-and medium-sized vessels.
Accompanying these compositional changes was the proliferation of endothelial cells to form plexiform lesions. In this study, endothelial cell obliteration of small and medium pulmonary vessels developed after the 14-day normoxic period. The SuHx+veh group showed luminal arterial obliteration in 10-15% of vessels, though lower than 30% seen in severe cases (Abe et al., 2010) .
RP5063 pharmacologic, structural, and functional effects
Dysfunctional 5-HT and/or endothelin signaling in PAH can lead to vascular fibrosis, vasoconstriction, and proinflammatory cytokine/ chemokine increase (e.g., TNF-α, IL-6, IL-8, LTB4, etc.). Clinical studies have reported that in patients: 1− a 10-to13-fold increased level of 5-HT in PAH patients (Ullmer et al., 1995) ; 2− a higher expression of 5-HT 1B/2A/2B/7 in the pulmonary arterial/vascular system (Launay et al., 2002) . The 5-HT 1B/2A receptors have been reported to play major roles in the regulation of pulmonary vasoconstriction and vasodilation. By binding to the 5-HT 2B receptor, RP5063 produced limited pulmonary smooth muscle hyperplasia in a dose-related manner, which complemented its dilatory effects. Both groups showed a significantly lower percentage of muscular tissue and higher percentage of non-muscular tissue in the small vessels. The RP-20 group had significantly thinner small vessel walls versus the SuHx+veh group. Both groups showed a lower extent of arteriole obliteration at 8%.
These effects limited serious hemodynamic consequences versus the SuHx+veh group. RP5063 produced significantly lower PAP Syst (both groups). While RP-20 group and Sil-50 groups displayed similar RSVP lowering, these effects were not significantly from the SuHx+veh group due to data variability. This prevention of the vasoconstriction by RP-20 resulted in a significantly higher SO 2 . Both dose groups lowered Fulton's index measurements, suggesting that RP5063, particularly the RP-10 group, might play a role in preventing RV hypertrophy.
RP5063 mitigated the effects of 5-HT in the pulmonary vasculature due to its moderate affinity for SERT and high affinity for 5-HT 2A/2B/7 receptors (Cantillon et al., 2017) . RP5063 can prevent the vasoconstriction via 5-HT 2A signaling and mitigate cell proliferation and vascular remodeling facilitated by 5-HT 2B signaling (Dumitrascu et al., 2011; Farber and Loscalzo, 2004) . Its role on the pulmonary vasculature related to its DA 2/3/4 -receptor effect is unknown.
Sildenafil effects
Sildenafil, a PDE-5 inhibitor approved for the management of symptoms of PAH, served as the positive control, consistent with routine practice with these models (Stenmark et al., 2009) . Its primary action involves the relaxation of pulmonary vessel smooth muscles by inhibiting PDE-5 (Barnett and Machado, 2006) .
Structurally, sildenafil showed a significantly lower percentage of muscular tissue, a higher percentage of non-muscular tissue, and thinner walls in small vessels, as compared with that seen in SuHx +veh. These observations suggest that sildenafil prevented the hyperplasia and hypertrophy caused by sustained contraction due to its vasodilatory effects. The vascular composition effects were significant versus both the SuHx+veh and RP5063 groups. However, in 13% of vessels, the sildenafil group showed a similar extent of obliteration to that seen in the SuHx group, in contrast to the 8% figure seen with RP5063.
Sildenafil had a lung weight similar to that seen in the SuHx+veh group, whereas both RP5063 groups had lower lung weights. This observation suggests the appearance of lung fibrosis, associated edema, or both in this group.
Functionally, sildenafil limited the RVSP and Fulton's index increases seen in the SuHx+veh group, suggesting a preventive effect on RV hypertrophy due to pulmonary vasculature pressure reduction. It significantly improved SO 2 compared with SuHx+veh. Its functional effects appeared comparable in magnitude to those seen with RP5063.
Chemokine effects
RP5063 possesses a high affinity 5-HT 7 receptor antagonist (Ki 2.7 nM); 5-HT 7 receptors expressed in endothelial and vascular smooth muscle cells regulate inflammatory cytokines/chemokines (e.g., TNF-α, LTB4, etc.) and antagonists can downregulate these factors (Engel et al., 2013) . LT-B4 causes pulmonary vascular remodeling by directly injuring luminal endothelial cells, promoting the growth of the smooth muscle cell layer of pulmonary arterioles, and enhancing human pulmonary artery adventitial fibroblast proliferation, migration, and differentiation. (Quan et al., 2015) .
Notable changes were seen with LT-B4. The SuHx+veh group showed higher levels than the no-SuHx group at induction, peaking on Day 21, and remaining high on Days 28 and 35. Both RP5063 doses prevented its release to more than one-half the optical density level seen on Day 21 within the SuHx group. This effect persisted to Day 28 with both doses and to Day 35 with RP-20. The effect of RP5063 on LT-B4 suggests that an additional mechanism might be involved with the amelioration of the structural and functional changes related to PAH. In comparison with the levels with RP5063, those in the Sil-50 group were 1.5-and 2.5-fold higher on Days 21 and 28. (Bhat et al., 2016) . The study involved treatment from Day 0 (MCT induction) through Day 28 (terminal surgery). While the effects of RP5063 appeared greater than those seen in the SuHx study, they followed the same apparent dose-dependent efficacy. In both studies, RP5063 and sildenafil displayed a significantly lower smallvessel wall thickness and percentage of muscular vessels. In the MCT study, RP5063 and sildenafil prevented the disease-induced increases in lower PAP Diast , PAP Syst , RV hypertrophy, and respiratory resistance.
Each model brings its own unique design features. Both produced similar symptoms, but from different phenomena. Differences in therapeutic efficacy are expected. MCT-induction, a classic PAH model, is characterized by acute/subacute damage to the peripheral arteries followed by an acute inflammatory phase (Gomez-Arroyo et al., 2016; Lalich et al., 1977; Stenmark et al., 2009) . In contrast, the SuHx model addresses the etiologic mechanisms involved in the endothelial cell hyperproliferation that characterizes the plexogenic arteriopathy in the peripheral pulmonary arteries in human PAH (Taraseviciene-Stewart et al., 2001) . It emanates from the concept that vascular endothelial growth factor (VEGF) is an important maintenance and differentiating factor for vascular endothelial cells. In chronically hypoxic rats, Su5416, through its VEGF-receptor inhibition, causes severe, irreversible PAH with intimal lesions, characterized as precapillary, smallvessel arterial endothelial proliferations (Taraseviciene-Stewart et al., 2001) . VEGF receptor blockade and chronic hypoxia results in these lesions and a persistent and progressive PAH, which lead to RV remodeling and failure, even after removal of the hypoxic stimulus.
Because pathology of SuHx model differs from that of the MCT model, the observations from these 2 models involving vehicle, RP5063, and sildenafil must be interpreted based on these differences. While functional effects seen in these 2 studies differed, it is notable that both models displayed treatment-responsive structural effects following PAH induction and development.
There were also several design-related differences. The MCT study contained a larger number of animals in each cohort, ranging from 8 to 10 per group (Bhat et al., 2016) . Treatment in the MCT study started on Day 0 and continued until Day 28; treatment in the present study started on Day 14 and continued until Day 35.
This delay in treatment initiation could be significant. Some of the underlying causes of the pathology were well established. Endothelial dysfunction and vascular smooth muscle remodeling were already evident by the time of treatment initiation. Hence, it is possible that the delay in initiation, along with the shorter duration of treatment, could have limited the clinical benefits of the treatments. In essence, they functioned more to remedy the established structural and functional changes that had been stimulated, rather than acting as a preventive intervention by being administered starting at Day 0 (Bhat et al., 2016) . These differences in treatment strategies might offer some valuable insight to the functional differences seen in these 2 studies.
Conclusions
PAH is a chronic, progressive disease that leads to death within 7 years in half of patients who receive current treatments (Benza et al., 2012) . RP5063 is a novel chemical entity that possesses a strong binding affinity for DA 2/3/4 and 5-HT 2A/2B/7 receptors and moderate affinity for SERT (Cantillon et al., 2017) . In this study, RP-10 and RP-20 doses of RP5063 prevented significant structural changes from occurring within the pulmonary vasculature induced by Sugen 5416. These changes included a lower percentage of muscular tissue and decreased wall thickness in the small arterioles of the pulmonary vasculature. The effects of Sil-50 on vascular composition and structure are unknown; they were similar to, but more pronounced than, that of RP5063. These structural changes produced by RP5063 reflect those seen in a separate study involving the MCT-induced model of PAH in rats (Bhat et al., 2016) . Unlike sildenafil, RP5063 also stemmed the release of the inflammatory mediator, LT-B4, which may have influenced remodeling within the pulmonary vasculature. These effects led to functional changes that included improved pulmonary hemodynamics, RV remodeling, and arterial oxygenation. Significant improvements were observed in SPP in both RP5063 dose groups and RVSP in the RP-10 group. Furthermore, SO 2 was restored to a normal level and was significantly higher than the SuHx+veh group in both the RP5063 dose groups and in the Sil-50 group. These structural and functional effects were notable considering that treatment was started 2 weeks after the initial induction, in which irreversible damage occurred, and was administered for only a 3-week period. Based on these observations, along with those from the MCT model (Bhat et al., 2016) , RP5063 represents a promising therapeutic option with the potential of being a disease-modifying treatment for PAH. Thus, RP5063 needs to be explored further for use in the treatment of PAH.
